US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Ultimovacs receives Orphan Drug Designation from EMA

Ultimovacs has been granted Orphan Drug Designation from the European Medicines Agency for its universal cancer vaccine, UV1, as a treatment for mesothelioma, a rare and aggressive form of cancer with limited therapeutic options. The designation was granted based on results from the phase II clinical trial NIPU and brings regulatory and commercial benefits to the development of the immunotherapy. BioStock reached out to CEO Carlos de Sousa for a comment.Read the interview with Carlose de Sousa at biostock.se: Ultimovacs receives Orphan Drug Designation from EMA - BioStock 

BioStock: Ultimovacs CEO - "Data could put us at the forefront of cancer vaccine field"

Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO Carlos de Sousa talked to BioStock about the results and what they mean for the oncology field.Watch the interview with Carlos de Sousa at biostock.se https://www.biostock.se/en/2023/11/data-could-put-ultimovacs-at-the-forefront-of-cancer-vaccine-field/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Ultimovacs reaches proof of concept with UV1 cancer vaccine

Ultimovacs has reported positive phase II overall survival data with its cancer vaccine candidate UV1 in mesothelioma. The data will be presented by the Principal Investigator of the NIPU trial, Professor Åslaug Helland, at the ESMO Congress 2023. BioStock spoke with the the Norwegian biotech’s Director Medical Affairs Espen Basmo Ellingsen to better understand the significance of these results.Read the interview with Espen Basmo Ellingsen at biostock.se: Ultimovacs reaches proof of concept with UV1 cancer vaccine - BioStock 

BioStock: Ultimovacs CMO explains phase II mesothelioma data

Ultimovacs has announced topline data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in mesothelioma. An independent review of the results has concluded that the primary endpoint, progression-free survival, has not been reached. Meanwhile a local assessment has found a statistically significant improvement in PFS for patients receiving UV1 treatment. BioStock spoke with Jens Bjørheim, CMO at Ultimovacs, to get a full overview of the results.Watch the interview with Jens Bjørheim at biostock.se: Ultimovacs CMO explains phase II mesothelioma data - BioStock 

BioStock: Ultimovacs in the fight against mesothelioma

Mesothelioma is a rare but aggressive form of cancer with limited treatment options. Norwegian biotech Ultimovacs is addressing the need for new therapies with its universal cancer vaccine UV1. BioStock got in touch with the Director Medical Affairs at Ultimovacs, Espen Basmo Ellingsen, to learn more about the overall burden caused by this disease as well as the phase II trial NIPU evaluating UV1 in combination with standard of care.Read the full interview with Espen Basmo Ellingsen at biostock.se: https://www.biostock.se/en/2023/06/ultimovacs-in-the-fight-against-mesothelioma/ This

BioStock: Ultimovacs updates INITIUM study timeline

The phase II INITIUM trial with Ultimovacs’ universal cancer vaccine UV1 in malignant melanoma was due for a data readout in the first half of 2023. However, disease progression is taking longer than expected, which is a good sign for patients in such a high risk group. The company has thus updated guidance for a readout to the second half of 2023. BioStock spoke with Ultimovacs’ CEO Carlos de Sousa to learn moreRead the interview with Carlos de Sousa at biostock.se: Ultimovacs updates INITIUM study timeline - BioStock 

BioStock: Ultimovacs on track to phase II readout

Cancer vaccines are quickly gaining popularity in the international biotech community, especially since household names like Moderna and BioNTech have stepped into the ring. Norwegian biotech Ultimovacs is poised to ride this wave of momentum as it approaches phase II readouts with its universal cancer vaccine UV1. BioStock spoke with CEO Carlos de Sousa to hear about the progress made in Q4 2022, and how UV1 could rival personalised mRNA vaccines.Read the interview with Carlos de Sousa at biostock.se: Ultimovacs på väg mot fas II-avläsning - BioStock 

BioStock: The innovative force behind Ultimovacs’ cancer vaccine

Promising clinical data reinforce the fact that Ultimovacs’ universal cancer vaccine UV1 has the potential to become a new line of treatment for cancer patients. The company’s broad clinical pipeline evaluating the candidate is the culmination of decades of research led by one of the pioneers in cancer immunotherapy, Professor Gustav Gaudernack. BioStock was able to get in touch with Professor Gaudernack, who is currently CSO at Ultimovacs, to learn more about his work.Read the interview with Professor Gustav Gaudernack at biostock.se: The innovative force behind Ultimovacs’ cancer

BioStock: Ultimovacs poised for major clinical transition

With its latest quarterly report, Norwegian immuno-oncology company Ultimovacs highlights the continued progress with its broad clinical programme evaluating universal cancer vaccine UV1. Patient recruitment is in full swing within all five of the company’s phase II trials, and encouraging survival data from their phase I UV1/pembrolizumab combination study in malignant melanoma were recently announced. With solid finances at its back, Ultimovacs is in a good position to reach significant clinical development milestones next year. BioStock spoke with CEO Carlos de Sousa to get his take.Read

BioStock: Ultimovacs shows positive three-year data in skin cancer

Norwegian biotech Ultimovacs has recently presented positive three-year data for patients with metastatic malignant melanoma treated with cancer vaccine UV1 in combination with anti-PD-1 checkpoint inhibitor pembrolizumab. The results show both promising overall survival and an effect on predictive biomarkers, which strengthens the company's belief in UV1 as a combination treatment with today's checkpoint inhibitors for solid tumours. BioStock contacted Espen Basmo Ellingsen, Director Medical Affairst Ultimovacs, to find out more.Read interview with Espen Basmo Ellingsen at biostock.se:

BioStock: Ultimovacs' malignant melanoma study fully recruited

Norwegian biotech Ultimovacs shows progress in the clinical trial of malignant melanoma despite challenges caused by the pandemic. The clinical-stage leader in immune-stimulatory cancer vaccines has now reached the recruitment goal in the INITIUM phase II trial of UV1. The study provides randomised data on the effectiveness of UV1 as an add-on to standard-of-care treatment. Topline progression-free survival data is expected in H1 2023.Read the article at biostock.se : https://www.biostock.se/en/2022/07/ultimovacs-malignant-melanoma-study-fully-recruited/

BioStock Studio: An in-depth look at Ultimovacs' cancer vaccine

The field of immuno-oncology is growing, and cancer vaccines are a big part of that. Norwegian biotech Ultimovacs is developing its own cancer vaccine technology platform. BioStock invited Sara Mangsbo, Chief Innovation Officer at Ultimovacs, to the Studio to learn more.Watch the interview with Sara Mangsbo at biostock.se : https://www.biostock.se/en/2022/05/an-in-depth-look-at-ultimovacs-cancer-vaccine/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Ultimovacs keeps delivering in Q1

Q1 saw Norwegian immuno-oncology company Ultimovacs advance on a number of fronts. The company’s clinical programmes with universal cancer vaccine UV1 and adjuvant platform TET have continued to progress steadily. Moreover, milestones were reached at the preclinical level as well as the intellectual property level.Read the article at biostock.se : https://www.biostock.se/en/2022/05/ultimovacs-keeps-delivering-in-q1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Ultimovacs protects cancer vaccine technology until 2037

Norwegian biotech Ultimovacs has announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office regarding its universal cancer vaccine UV1 in combination with various classes of checkpoint inhibitors. Once formally granted, the patent will protect Ultimovacs’ technology until at least June 2037.Read the article at biostock.se : https://www.biostock.se/en/2022/04/ultimovacs-protects-cancer-vaccine-technology-until-at-least-2037/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Ultimovacs to ride wave of positive momentum in 2022

Ultimovacs’ Q4 report has been released, and it reflects the company’s robust progress with its universal cancer vaccine candidate UV1 during 2021. This, paired with important regulatory decisions by the FDA, has given Ultimovacs positive momentum going into 2022. The company’s CEO Carlos de Sousa spoke to BioStock about the company´s achievements and how he plans to keep up the strong momentum into 2022.Read the interview with Carlos de Sousa at biostock.se: https://www.biostock.se/en/2022/02/ultimovacs-to-ride-wave-of-positive-momentum-in-2022/ This is a press release from BioStock -

BioStock: Ultimovacs progresses to last cohort in TENDU study

Ultimovacs continues to progress with its phase I TENDU study testing the company’s TET cancer vaccine platform in prostate cancer patients. The company has announced moving on to its last of three patient cohorts after no safety concerns were found in the first two.Read the article at biostock.se : https://www.biostock.se/en/2022/02/ultimovacs-progresses-to-last-cohort-in-tendu-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs has announced that the first patient has been enrolled in a phase II trial designed to assess the impact of the company’s universal cancer vaccine on the standard of maintenance care in ovarian cancer. The primary outcome measure is progression-free survival for UV1 in combination with AstraZeneca’s durvalumab+olaparib versus olaparib alone.Read the article at biostock.se : https://www.biostock.se/en/2021/12/ultimovacs-sees-first-patient-enrolled-in-dovacc-trial/ This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: Ultimovacs’ UV1 granted orphan drug designation

Ultimovacs has announced being granted Orphan Drug Designation by the FDA for its universal cancer vaccine UV1 in the treatment of malignant melanoma. The news comes barely one month after UV1 was granted Fast Track by the FDA, meaning that Ultimovacs’ candidate continues to solidify its stance as a promising cancer immunotherapy.Read the article at biostock.se : https://www.biostock.se/en/2021/12/ultimovacs-uv1-granted-orphan-drug-designation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Ultimovacs progresses on several fronts

The year’s third quarter saw Norwegian immuno-oncology developer Ultimovacs make several key advancements. Not only has the company progressed with its phase I clinical development of universal cancer vaccine UV1, but it has also announced the initiation of a fifth phase II trial with the candidate. To top things off, among other news, Ultimovacs was awarded dual Fast Track designation for UV1 from the FDA and raised 270 MNOK in a private placement.Read the article at biostock.se : https://www.biostock.se/en/2021/11/ultimovacs-progresses-on-several-fronts/

BioStock Studio: Ultimovacs reaches key milestones with UV1

Norwegian Ultimovacs has made some big announcements recently, including discussions for a fifth phase II clinical trial with universal cancer vaccine UV1, a private placement of 270 MNOK to fund the trial and other projects, plus the FDA’s decision to grant dual Fast Track designation for UV1 in advanced melanoma. To discuss this and more, Ultimovacs’ CEO Carlos de Sousa linked up to the BioStock Studio remotely from Oslo for a Q&A.Watch the interview with Carlos de Sousa at biostock.se : https://www.biostock.se/en/2021/11/biostock-studio-ultimovacs-reaches-

BioStock: Ultimovacs launches fifth phase II trial with UV1

Norwegian Ultimovacs continues to expand its clinical development pipeline with universal cancer vaccine UV1. This week, the company announced its plan to initiate a fifth phase II trial with the candidate – a combination study with checkpoint inhibitor pembrolizumab in non-small cell lung cancer. The study will be conducted at 8-10 sites across Norway and led by principal investigator Professor Odd Terje Brustugun.Read the article at biostock.se : https://www.biostock.se/en/2021/10/ultimovacs-launches-fifth-phase-ii-trial-with-uv1/ This is a press release

BioStock: Ultimovacs receives dual FDA Fast Track for UV1

Ultimovacs’ mission to develop a cancer vaccine just received a significant boost. The FDA has granted dual Fast Track designation for the company’s candidate UV1 as an add-on therapy to checkpoint inhibitors in advanced malignant melanoma patients. The designation potentially provides expedited review of UV1 for approval.Read the article at biostock.se : https://www.biostock.se/en/2021/10/ultimovacs-receives-dual-fda-fast-track-for-uv1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Positive phase I data for Ultimovacs

Biotech company Ultimovacs continues to strengthen the clinical evidence for its universal cancer vaccine UV1. On Wednesday morning the company could announce positive results from a phase I study of UV1 in combination with the checkpoint inhibitor pembrolizumab. The combination, which was tested in patients with metastatic malignant melanoma, showed the very encouraging survival rate of 80 per cent after 24 months.Read the full article at biostock.se:https://www.biostock.se/en/2021/10/positive-phase-i-data-for-ultimovacs/ This is a press release from BioStock - Connecting Innovation &

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe